La vendita allo scoperto per Ainos dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Ainos. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Ainos (NASDAQ:AIMD) Azioni, Report sulle vendite allo scoperto

Ainos

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Ainos Inc

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 14.56% on an annualized basis producing an average annual return of 28.37%. Currently, Insmed has a market capitalization of $12.86 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 5 years ago, it would be worth $367.67 today based on a price of $71.07 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744752627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

INSM

Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years

Global

NVDA

The U.S. Government Informed Nvidia That The USG Requires A License For Export To China (Including Hong Kong And Macau) And D:5 Countries The Company's H20 Integrated Circuits And Any Other Circuits Achieving The H20's Memory Bandwidth, Interconnect Bandwidth; The USG Informed The Company That The License Requirement Will Be In Effect For The Indefinite Future; Q1 Results Are Expected To Include Up To ~$5.5B Of Charges Associated With H20 Products For Inventory, Purchase Commitments, And Related Reserves

General

NSYS

Nortech Systems Announces An Expansion In Its Fiber Optic Capabilities With The Integration Of MT Connectors, Enhancing Solutions For Aerospace and Defense

Summary 2024 Financial Results
Total Revenue Total revenue for the fiscal year ended December 31, 2024 was $33.9 million compared to $30.1 million in the prior year.
Revenue for 2024 primarily consisted of approximately $18.3 million from XpresSpa locations, $430,000 from Treat locations and approximately $13.1 million from XpresTest, which includes XWELL's bio-surveillance partnership and its HyperPointe business. Naples Wax Center accounted for approximately $2.1 million.
Total Cost of Sales Total cost of sales for the fiscal year ended December 31, 2024 were approximately $25.0 million compared to approximately $26.4 million in the prior year.
General and Administrative Expenses; Salaries and Benefits General and administrative expenses for the fiscal year ended December 31, 2024 were approximately $12.5 million compared to approximately $13.0 million in the prior year.
Salaries and benefits for the fiscal year ended December 31, 2024 were approximately $7.5 million compared to approximately $8.0 million in the prior year.
Total Operating Expenses Total operating expenses for the fiscal year ended December 31, 2024 were approximately $25.6 million compared to approximately $31.9 million in the prior year.
Operating Loss The operating loss for the fiscal year ended December 31, 2024 totaled approximately ($16.7) million compared to approximately ($28.2) million in the prior year.
Net Loss Attributable to XWELL Net loss attributable to XWELL for the fiscal year ended December 31, 2024 totaled approximately ($16.9) million compared to approximately ($27.7) million in the prior year.

Earnings

XWEL

XWELL FY24 Revenue $33.9M Up From $30.1M YoY

Offerings

Buybacks

CALM

Cal-Maine Foods Announces An Underwritten Public Offering Of 3,024,287 Shares Of Its Common Stock By The Company's Founder's Family; Intends To Purchase Up To $50M Of Shares Of Its Common Stock Being Sold In Connection With The Offering

BKNG rises over 1.5% after the Power Inflow Signal
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15201652/Screenshot-2025-04-15-at-4.10.17%E2%80%AFPM-1024x823.png" alt="" class="wp-image-10715" /></figure>
Booking Holdings, Inc. (BKNG) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:21 AM on April 15th, a significant trading signal occurred for Booking Holdings, Inc. (BKNG) as it demonstrated a Power Inflow at a price of $4544.82. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Booking&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Booking&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BKNG, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $4544.82. The returns on the High price ($4615.65) and Close price ($4612.44) after the Power Inflow are respectively 1.6% and 1.5%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. They were close today but that is not always the case.
Results are not indicative of future results

Equities

WIIM

Technicals

Opinion

Signals

Markets

BKNG

Booking Stock Closes Up 1.5% After Key Signal

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) has outperformed the market over the past 5 years by 6.71% on an annualized basis producing an average annual return of 20.51%. Currently, JPMorgan Chase has a market capitalization of $647.89 billion. 
Buying $100 In JPM: If an investor had bought $100 of JPM stock 5 years ago, it would be worth $244.94 today based on a price of $233.13 for JPM at the time of writing.
<h3>JPMorgan Chase's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744751710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Although it has not yet finalized its full financial results for the first quarter ended March&nbsp;31, 2025, Semler Scientific,&nbsp;Inc., or Semler Sci, is providing select preliminary unaudited financial information for the first quarter ended March&nbsp;31, 2025 and an update on its Bitcoin holdings as of March&nbsp;31, 2025.
&nbsp;
Semler Sci anticipates reporting for the first three months ended and as of March&nbsp;31, 2025:
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Revenues of $8.8 to $8.9 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Loss from operations of $1.3 to $1.5 million (which includes approximately $1.5 million of non-cash stock compensation, $0.4 million in state sales and use tax accrual, and $0.4 million in legal fees relating to the U.S. Department of Justice, or DOJ, civil investigative demand, or CID).</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Unrealized loss from the change in fair value of bitcoin holdings since December&nbsp;31, 2024 of approximately $41.8 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Bitcoin holdings of 3,192 bitcoins as of March&nbsp;31, 2025, valued at approximately $263.5 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Contingent liability relating to the settlement of DOJ CID of approximately $29.75 million.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>·</td>
<td>Cash, restricted cash and cash equivalents as of March&nbsp;31, 2025 of approximately $9.9 million.</td>
</tr>
</tbody>
</table>
</figure>

Guidance

SMLR

Semler Scientific Expects Q1 Revenues Of $8.8M-$8.9M; Holds 3,192 Bitcoins Valued At ~$263.5M

J.B. Hunt Transport Services Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) reported financial results for the first quarter after the market close on Tuesday. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/04/b44825782/j-b-hunt-transport-services-inc-reports-u-s-gaap-revenues-net-earnings-and-earnings-per-share-for-">transportation company&#8217;s report</a>.
<ul>
<li>Q1 Revenue: $2.92 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $2.91 billion</li>
</ul>
<ul>
<li>Q1 EPS: $1.17, versus estimates of $1.19</li>
</ul>
Total revenue was down 1% on a year-over-year basis, driven by a&nbsp;5%&nbsp;decrease in average truck count in Dedicated Contract Services,&nbsp;15%&nbsp;fewer stops in Final Mile Services,&nbsp;13%&nbsp;fewer loads in Integrated Capacity Solutions and an&nbsp;8%&nbsp;decrease in Truckload gross revenue per load.
Revenue weakness in the aforementioned categories was partially offset by Intermodal revenue growth of&nbsp;5%, primarily fueled by an&nbsp;8%&nbsp;increase in load volume.
Debt increased to $1.58 billion as of March 31, up from $1.48 billion at the end of 2024. The company ended the quarter with $43 million in cash and cash equivalents.
See Also: <a href="https://www.benzinga.com/news/earnings/25/04/44826372/interactive-brokers-reports-mixed-q1-results-declares-4-for-1-forward-stock-split">Interactive Brokers Reports Mixed Q1 Results, Declares 4-For-1 Forward Stock Split </a>
J.B. Hunt said it repurchased approximately 1.4 million shares of its common stock in the first quarter for approximately $234 million. The company had approximately $650 million remaining under its buyback at quarter&#8217;s end.
JB Hunt did not provide forward guidance in the earnings release. Management will further discuss the quarter on a conference call scheduled for 5 p.m. ET.
JBHT Price Action: <a href="http://benzinga.com/quote/jbht">JB Hunt shares</a> were down 6.48% after-hours, trading at $126.35 at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a> data.
Photo: Shutterstock.

Movers

JBHT

JB Hunt Q1 Earnings: Revenue Beat, EPS Miss, Shares Skid

<h3>Gainers</h3>
<ul>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) shares moved upwards by 6.8% to $2.68 during Tuesday's after-market session. The market value of their outstanding shares is at $75.2 million. </li>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares increased by 4.98% to $0.44. The company's market cap stands at $10.8 million. </li>
<li>iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) shares increased by 4.94% to $1.91. The company's market cap stands at $58.5 million. </li>
<li>Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) stock increased by 4.91% to $6.19. The market value of their outstanding shares is at $224.8 million. </li>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) shares rose 4.77% to $0.87. The company's market cap stands at $19.6 million. </li>
<li>Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) stock moved upwards by 4.71% to $12.65. The company's market cap stands at $807.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) shares decreased by 6.4% to $0.64 during Tuesday's after-market session. The company's market cap stands at $8.8 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock declined by 6.32% to $6.08. The market value of their outstanding shares is at $66.9 million. </li>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) stock decreased by 6.26% to $1.05. The market value of their outstanding shares is at $42.1 million. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock declined by 6.08% to $0.36. The market value of their outstanding shares is at $106.3 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares fell 5.16% to $0.92. The market value of their outstanding shares is at $1.7 million. </li>
<li>Envirotech Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) shares declined by 4.99% to $0.25. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGFV

EVTV

FLYE

GROV

IRBT

JFBR

JZXN

LSEA

PTLO

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock moved upwards by 72.5% to $3.33 during Tuesday's after-market session. The company's market cap stands at $87.7 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 17.69% to $0.69. The company's market cap stands at $16.5 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock rose 10.57% to $4.6. The company's market cap stands at $8.7 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares rose 10.0% to $1.1. The market value of their outstanding shares is at $18.3 million. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) shares moved upwards by 9.38% to $0.89. The company's market cap stands at $7.6 million. </li>
<li>Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) shares increased by 8.41% to $0.47. The market value of their outstanding shares is at $106.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 9.8% to $0.46 during Tuesday's after-market session. The company's market cap stands at $5.2 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 8.35% to $0.37. The company's market cap stands at $1.7 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock fell 7.87% to $0.42. The market value of their outstanding shares is at $10.6 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock decreased by 6.96% to $0.67. The market value of their outstanding shares is at $1.1 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares declined by 6.89% to $0.19. The company's market cap stands at $2.2 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares declined by 6.25% to $0.74. The market value of their outstanding shares is at $46.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

DWTX

ENTO

ICAD

IRIX

LCTX

MTVA

SLRX

SNSE

SYRA

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) stock moved upwards by 14.0% to $3.1 during Tuesday's after-market session. The company's market cap stands at $34.1 million. The company's, Q4 earnings came out today. </li>
<li>Li Bang International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBGJ#NASDAQ">LBGJ</a>) shares rose 11.11% to $1.4. The market value of their outstanding shares is at $26.2 million. </li>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) stock increased by 7.87% to $1.78. The market value of their outstanding shares is at $49.8 million. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) shares moved upwards by 7.06% to $0.67. The company's market cap stands at $14.9 million. </li>
<li>United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) shares rose 6.75% to $71.52. The market value of their outstanding shares is at $23.4 billion. As per the news, the Q1 earnings report came out today. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares moved upwards by 5.7% to $0.45. The company's market cap stands at $14.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares declined by 9.1% to $0.24 during Tuesday's after-market session. The market value of their outstanding shares is at $47.2 million. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock fell 7.69% to $1.08. The market value of their outstanding shares is at $17.5 million. </li>
<li>JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) shares declined by 6.55% to $126.27. The company's market cap stands at $12.6 billion. As per the press release, Q1 earnings came out today. </li>
<li>Intercont (Cayman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCT#NASDAQ">NCT</a>) stock decreased by 6.25% to $7.51. The market value of their outstanding shares is at $203.1 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares declined by 4.98% to $1.05. The market value of their outstanding shares is at $126.9 million. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) stock declined by 4.33% to $1.55. The market value of their outstanding shares is at $33.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXST

HOVR

HTCO

LBGJ

LNZA

NCEW

PPSI

RAYA

SFHG

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) shares moved upwards by 6.5% to $1.3 during Tuesday's after-market session. The company's market cap stands at $12.0 million. As per the news, the Q4 earnings report came out today. </li>
<li>Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) shares rose 5.01% to $20.74. The company's market cap stands at $936.0 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) shares moved upwards by 4.98% to $0.43. The market value of their outstanding shares is at $7.9 million. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares increased by 4.97% to $0.16. The company's market cap stands at $11.5 million. </li>
<li>Olo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) stock rose 4.9% to $6.41. The company's market cap stands at $1.0 billion. </li>
<li>CCC Intelligent Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>) shares increased by 4.75% to $9.26. The market value of their outstanding shares is at $6.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock declined by 13.3% to $1.3 during Tuesday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) shares decreased by 10.26% to $4.2. The market value of their outstanding shares is at $117.1 million. </li>
<li>Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) stock decreased by 7.67% to $3.13. The market value of their outstanding shares is at $493.1 million. </li>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) stock declined by 7.49% to $4.45. The company's market cap stands at $2.2 million. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) stock fell 6.95% to $0.51. The market value of their outstanding shares is at $1.6 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares decreased by 6.37% to $3.0. The company's market cap stands at $82.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUUD

BNZI

CCCS

CXDO

EVLV

GRYP

IFBD

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MRIN

UCTT

12 Information Technology Stocks Moving In Tuesday's After-Market Session

KORE

KORE Reschedules Earnings Release and Conference Call, Expects To Issue Its Q4 And FY24 Financial Results After Market Close On April 30, 2025

Management

Lithia Motors Announces That Adam Chamberlain Will Transition From His Current Role As Executive Vice President And Chief Operating Officer 
Effective June 1, 2025

Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Privia Health Gr, revealing an average target of $29.2, a high estimate of $40.00, and a low estimate of $23.00. This upward trend is evident, with the current average reflecting a 11.03% increase from the previous average price target of $26.30.
<img src="https://www.benzinga.com/files/images/story/2025/1744750864_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Privia Health Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Ha &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $26.00&#x7C;$24.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $23.00&#x7C;$21.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $28.00&#x7C;$27.00 &#x7C; 
&#x7C;Matthew Sheerin &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $30.00&#x7C;$30.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $30.00&#x7C;$30.00 &#x7C; 
&#x7C;Constantine Davides &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Market Outperform&#x7C; $29.00&#x7C;$26.00 &#x7C; 
&#x7C;Richard Close &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $30.00&#x7C;$29.00 &#x7C; 
&#x7C;Sean Wieland &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $40.00&#x7C;$25.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $30.00&#x7C;$25.00 &#x7C; 
&#x7C;Constantine Davides &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $26.00&#x7C;$26.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Privia Health Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Privia Health Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Privia Health Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Privia Health Gr's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Privia Health Gr analyst ratings.</a>
<h2>Delving into Privia Health Gr's Background</h2>
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
<h3>Privia Health Gr: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Privia Health Gr's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Privia Health Gr's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.95%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.7%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.39%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

PRVA

Assessing Privia Health Gr: Insights From 10 Financial Analysts

During the last three months, 9 analysts shared their evaluations of Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $105.56, a high estimate of $143.00, and a low estimate of $83.00. Experiencing a 10.71% decline, the current average is now lower than the previous average price target of $118.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1744750857_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Lear among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Dan Levy &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $85.00&#x7C;$115.00 &#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $83.00&#x7C;$102.00 &#x7C; 
&#x7C;Mark Delaney &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $84.00&#x7C;$117.00 &#x7C; 
&#x7C;Adam Jonas &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $125.00&#x7C;$135.00 &#x7C; 
&#x7C;Chris McNally &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $110.00&#x7C;$125.00 &#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $102.00&#x7C;$104.00 &#x7C; 
&#x7C;Colin Langan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $103.00&#x7C;$99.00 &#x7C; 
&#x7C;Ryan Brinkman &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $143.00&#x7C;$147.00 &#x7C; 
&#x7C;Dan Levy &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $115.00&#x7C;$120.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lear. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lear compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Lear's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lear's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LEA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lear analyst ratings.</a>
<h2>All You Need to Know About Lear</h2>
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns most of its revenue from the seating segment.
<h3>Financial Insights: Lear</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Lear's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -2.17%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Lear's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Lear's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.91%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Lear's ROA excels beyond industry benchmarks, reaching 0.61%. This signifies efficient management of assets and strong financial health.
Debt Management: Lear's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.65.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Have This To Say About Lear

4 analysts have expressed a variety of opinions on Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Amentum Holdings, revealing an average target of $24.75, a high estimate of $30.00, and a low estimate of $21.00. This current average represents a 10.0% decrease from the previous average price target of $27.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744750848_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Amentum Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andre Madrid &#x7C;BTIG &#x7C;Announces &#x7C;Buy &#x7C; $30.00&#x7C;- &#x7C; 
&#x7C;Tobey Sommer &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $24.00&#x7C;$31.00 &#x7C; 
&#x7C;Noah Poponak &#x7C;Goldman Sachs &#x7C;Announces &#x7C;Neutral &#x7C; $21.00&#x7C;- &#x7C; 
&#x7C;Ken Herbert &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $24.00&#x7C;$24.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amentum Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Amentum Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Amentum Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Amentum Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AMTM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Amentum Holdings analyst ratings.</a>
<h2>Discovering Amentum Holdings: A Closer Look</h2>
Amentum Holdings Inc is engaged in engineering and technology solutions. The United States and its allies trust it to address their technical and complex scientific, security, and sustainability challenges.
<h3>Unraveling the Financial Story of Amentum Holdings</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Amentum Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 72.26%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.35%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.27%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Amentum Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 1.05, Amentum Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMTM

What Analysts Are Saying About Amentum Holdings Stock

6 analysts have shared their evaluations of Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $66.67, with a high estimate of $130.00 and a low estimate of $45.00. A 13.61% drop is evident in the current average compared to the previous average price target of $77.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1744750840_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Innovative Ind Props. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alexander Goldfarb &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Underweight &#x7C; $45.00&#x7C;$55.00 &#x7C; 
&#x7C;Merrill Ross &#x7C;Compass Point &#x7C;Lowers &#x7C;Sell &#x7C; $50.00&#x7C;$60.00 &#x7C; 
&#x7C;Alexander Goldfarb &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Underweight &#x7C; $55.00&#x7C;$60.00 &#x7C; 
&#x7C;Merrill Ross &#x7C;Compass Point &#x7C;Lowers &#x7C;Neutral &#x7C; $60.00&#x7C;$78.00 &#x7C; 
&#x7C;Alexander Goldfarb &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Underweight &#x7C; $60.00&#x7C;$70.00 &#x7C; 
&#x7C;Scott Fortune &#x7C;Roth MKM &#x7C;Lowers &#x7C;Buy &#x7C; $130.00&#x7C;$140.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Innovative Ind Props. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Innovative Ind Props compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Innovative Ind Props's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Innovative Ind Props's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IIPR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Innovative Ind Props analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Innovative Ind Props: A Closer Look</h2>
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
<h3>Innovative Ind Props: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Innovative Ind Props's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -3.05%. This indicates a decrease in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 50.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Innovative Ind Props's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Innovative Ind Props's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.63%, the company showcases efficient use of assets and strong financial health.
Debt Management: Innovative Ind Props's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IIPR

Forecasting The Future: 6 Analyst Projections For Innovative Ind Props

During the last three months, 7 analysts shared their evaluations of Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Synopsys, revealing an average target of $604.0, a high estimate of $660.00, and a low estimate of $520.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.41%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744750828_0_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Synopsys by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jason Celino &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $555.00&#x7C;$690.00 &#x7C; 
&#x7C;Siti Panigrahi &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $600.00&#x7C;$650.00 &#x7C; 
&#x7C;Clarke Jeffries &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $653.00&#x7C;$655.00 &#x7C; 
&#x7C;Charles Shi &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $650.00&#x7C;$650.00 &#x7C; 
&#x7C;Joe Quatrochi &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $520.00&#x7C;$540.00 &#x7C; 
&#x7C;Blair Abernethy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $660.00&#x7C;$660.00 &#x7C; 
&#x7C;Lee Simpson &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $590.00&#x7C;$625.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Synopsys. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Synopsys compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Synopsys's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Synopsys's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNPS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Synopsys analyst ratings.</a>
<h2>Discovering Synopsys: A Closer Look</h2>
Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
<h3>A Deep Dive into Synopsys's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Synopsys's revenue growth over a period of 3M has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately -3.68%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.32%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.23%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.26%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.07.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNPS

What 7 Analyst Ratings Have To Say About Synopsys

Press Releases

Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation

Ainos and ugo to Develop the World's First Robot With a Sense of Smell

Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here

Ainos Reports Full Year 2024 Financial Results

Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing

Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose's Potential in Chip Manufacturing and More

Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025

Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling

Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan

Comments

Ainos

Vendite allo scoperto

Ainos (NASDAQ:AIMD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO